INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA Biologics, Inc. of Class Action Lawsuit and Upcoming Deadlines

ADMA Biologics faces a securities class action alleging fraud or other unlawful practices, tied to claims from a March 24, 2026 Culper Research report that “channel stuffing” and an undisclosed related-party distributor inflated reported growth (estimating revenues fell 3% in 2025 vs. +20% reported). Following the report, ADMA shares dropped 16.63% (down $2.26 to $11.33), and after a March 26 Cantor Fitzgerald downgrade over ADMA’s insufficient response, the stock fell another 13.91% (down $1.34 to $8.29). The filing increases litigation/reputational risk for the company and could pressure sentiment even if no new financial data were released.

Analysis

This is less about the lawsuit itself than the market moving from a growth multiple to a credibility discount. For a small-cap specialty biotech like ADMA, any hint that revenue was pulled forward or routed through non-arm’s-length channels can trigger an abrupt reset in EV/sales before the P&L fully reflects the issue. The key second-order effect is tighter access to capital: even if the underlying product demand is intact, counterparties, lenders, and future investors will demand a higher risk premium until disclosure quality is repaired.

Near term, the damage is usually in the stock, not the business. Over the next 1-3 months, the critical catalyst is whether management can produce granular, independently verifiable evidence on distributor inventory, receivables aging, and end-market sell-through; a vague defense tends to prolong de-rating and keep borrow demand elevated. Over 6-18 months, the more important question is whether this becomes an operating thesis break versus a one-off litigation overhang — if revenue quality was overstated, consensus margin and growth assumptions for the next two years are likely still too high.

The contrarian risk is a squeeze if the market has already priced in the worst-case scenario and short interest is crowded; litigation headlines can keep the tape weak, but a clean auditor or detailed channel data dump could force fast covering. What would falsify the bearish thesis is a company response that reconciles growth with hard data: distributor inventory normalizing, no unusual related-party economics, and no revision to guidance or collections. Absent that, the likely path is multiple compression first, then earnings revisions later.

Key Decisions for Investors

• Short ADMA on strength or into any relief rally; trade horizon 2-8 weeks. Risk/reward is attractive if credibility concerns persist, but cover quickly if management releases audited channel inventory and receivables data that directly rebuts the allegations.
• If borrow is tight, use put spreads on ADMA with 1-3 month tenor rather than outright puts; the catalyst is a slow-burn credibility reset, so defined-risk downside exposure is preferable to chasing a binary litigation headline.
• Pair trade: short ADMA / long GRFS as a relative-value expression on revenue quality and disclosure risk. The trade works if the market starts valuing transparent peer fundamentals over contested growth narratives over the next quarter.
• Watch for a post-headline squeeze above the prior reaction-day high; if ADMA reclaims that level on volume without a substantive disclosure response, the bearish thesis is weakened and the trade should be reduced.